Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study

Graves Disease Clinical Trial

— GPCBasedow  

Official title:

Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02798965
• Other study ID #: AOL10-DR-DESAILLOUD
• Status: Completed
• Phase: N/A
• First received: June 9, 2016
• Last updated: June 15, 2016
• Start date: December 2010
• Est. completion date: May 2014

Study information

• Verified date: June 2016
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé
• Study type: Interventional

Clinical Trial Summary

Lymphocytic thyroiditis is the most common autoimmune disease, usually affecting young women. Although the aetiology and pathogenesis remain obscure, the most widely accepted hypothesis is an interaction between a genetic predisposition and an environmental trigger factor such as viral infection. Parvovirus infections have been proposed as trigger factors for Hashimoto's thyroiditis and Graves' disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Graves' disease :patients treated for Graves' disease, the diagnosis date less than 4 months

• Control : patients cared for nodules or goiter

Exclusion Criteria:

• Patients undergoing immunosuppressive therapy including corticosteroids

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Graves Disease

Intervention

Biological:
• serodiagnosis

Locations

Country	Name	City	State
France	CHU Amiens	Amiens

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	prevalence of circulating parvovirus genome		Day 0	No